Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2008

View Archived Issues

Promising phase II results of idebenone in Duchenne muscular dystrophy

In vivo antitumor efficacy seen with Trop-2 antibody AR47A6.4.2

Preclinical studies test IMGN-901 against ovarian cancer, multiple myeloma

OPL-CCL2-LPM active in mouse model of MS

Novel analgesic agents disclosed in recent patent literature

FDA approves Alcon's Patanase nasal spray for seasonal allergic rhinitis

Santarus is to terminate U.S. copromotion agreement with Otsuka for Zegerid

MedImmune initiates phase I and phase II clinical trials of anti-IL-13 antibody CAT-354

DSMB recommends continuation of Anthera's phase II IMPACTS clinical trial of A-001

Paratek completes USD 40 million private placement to finance phase III studies of PTK-0796

Zelos and Aegis enter collaboration for intranasal delivery of ZT-031 for osteoporosis

Lev Pharmaceuticals submits complete response to FDA for Cinryze for hereditary angioedema

New PPAR agonists evaluated for lipid effects in mice

Modern Biosciences initiates phase I rimcazole trial in cancer

Recent patents report new treatment options for inflammatory and autoimmune diseases

Shionogi receives marketing and manufacturing approval for Irbetan

Boston Scientific acquires CryoCor for approximately USD 17.6

Insmed receives U.K. approval to initiate phase I study of follow-on biologic of Neupogen

Pfizer and Avant enter into licensing agreement for EGFRvIII vaccine CDX-110

Sepracor launches Omnaris nasal spray for allergic rhinitis in the U.S.

Arpida reports positive results from two pivotal phase III trials with iclaprim in cSSSI

GSK and Regulus enter strategic alliance to develop microRNA-targeted therapeutics

Orion seeks expanded indication for Stalevo in Parkinson's disease in U.S. and Europe

Renovo reports positive results from two phase II clinical trials of Juvista for scars

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...